Clinical Trials on Stage IB Breast Cancer in Canada

Total 973 results

Ohio State University Comprehensive Cancer Center

Recruiting

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer

United States, Canada
NSABP Foundation Inc
National Cancer Institute (NCI); Radiation Therapy Oncology Group

Active, not recruiting

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Stage II Breast Cancer | Stage IB Breast Cancer

United States, Canada, Israel, Puerto Rico, Korea, Republic of, Japan, Ireland
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Hormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Progesterone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Canada, Puerto Rico, Ireland
University of Toronto

Completed

Feasibility of a Remotely-Delivered Yoga Intervention on Cognitive Function in Breast Cancer Survivors

Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Seagen Inc.

Recruiting

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Terminated

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

Canada
University Health Network, Toronto

Recruiting

Virtual Rehabilitation for Cancer Survivors

Lymphoma | Lymphoproliferative Disorders | Breast Cancer Stage I | Breast Cancer Stage II | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Breast Cancer Stage III | Colorectal Cancer Stage I | Head and Neck Cancer Stage III | Breast Cancer, Stage 0 | Head and Neck Cancer Stage I | Head and Neck Cancer...

Canada
Ontario Clinical Oncology Group (OCOG)
Cancer Care Ontario

Completed

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer (PET ABC)

Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4) | Stage IIb Breast Cancer (T3N0)

Canada
Ottawa Hospital Research Institute

Completed

Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (REaCT-RETT)

Early-stage Breast Cancer

Canada
Ottawa Hospital Research Institute

Active, not recruiting

Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) (REaCT-ZOL)

Early-stage Breast Cancer

Canada
Juravinski Cancer Center

Completed

Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer (MELO-D)

Early Stage Breast Cancer

Canada
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
British Columbia Cancer Agency

Active, not recruiting

Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant (PBSI)

Early Stage Breast Cancer

Canada
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States, Canada
Ottawa Hospital Research Institute

Recruiting

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy (REaCT-OGF)

Early-stage Breast Cancer

Canada
NRG Oncology
National Cancer Institute (NCI)

Suspended

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer

United States, Canada
Lawson Health Research Institute

Recruiting

Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer (Pre-PLaN)

Non-small Cell Lung Cancer Stage IB (Resectable) | Non-small Cell Lung Cancer Stage II (Resectable) | Non-small Cell Lung Cancer Stage ⅢA (Resectable)

Canada
Ottawa Hospital Research Institute

Active, not recruiting

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Early-stage Breast Cancer

Canada
National Cancer Institute (NCI)

Completed

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Ovarian Carcinoma | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Skin Melanoma | Recurrent Non-Small Cell... and other conditions

Canada
Exactis Innovation
Knight Therapeutics

Completed

RWD Study in HER2+ mBC Patients in Third-Line Therapy

Breast Cancer Stage IV

Canada
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

Canada
Ottawa Hospital Research Institute

Completed

Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients (REaCT-TAPS)

Pain Syndrome | Early-stage Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
University Health Network, Toronto; Princess Margaret Hospital, Canada

Completed

A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer (AToM)

Early Stage Breast Cancer

Canada
British Columbia Cancer Agency
Janssen Research & Development, LLC

Withdrawn

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer

Canada
McMaster University
Canadian Breast Cancer Foundation

Completed

Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers

Breast Cancer Invasive Nos | Stage 0 Breast Carcinoma

Canada
SOLTI Breast Cancer Research Group

Not yet recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV

Spain
Jewish General Hospital
Quebec Breast Cancer Foundation

Recruiting

Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer (TADEN)

Sentinel Lymph Node | Breast Cancer Female | Lymph Node Metastases | Early-stage Breast Cancer | Axillary Metastases

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Canadian Cancer Trials Group

Active, not recruiting

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

Stage II Breast Cancer | Stage IIIA Breast Cancer

United States, Canada, Puerto Rico
Ottawa Hospital Research Institute

Completed

A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia (REaCT-G2)

Early Stage Breast Cancer

Canada
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

Stage IIIA Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage 0 Breast Cancer AJCC v6 and v7

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States, Canada
National Cancer Institute (NCI)

Terminated

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Stage I Uterine Corpus Cancer AJCC v7 | Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Cervical Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage II Vaginal Cancer AJCC v6 and v7 and other conditions

United States, Canada
National Cancer Institute (NCI)
AstraZeneca

Active, not recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditions

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Canadian Cancer Trials Group

Active, not recruiting

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma | Ductal Breast Carcinoma | Tubular Breast Carcinoma | Medullary Breast Carcinoma

United States, Canada
Ottawa Hospital Research Institute

Completed

A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study) (React-G)

Early Stage Breast Cancer

Canada
Spanish Breast Cancer Research Group
AECC_Asociación Española contra el Cáncer

Recruiting

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

Invasive Breast Cancer Early Stages

Spain
SOLTI Breast Cancer Research Group
Novartis; UNICANCER

Recruiting

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

Breast Cancer Stage II

Spain, France, Portugal
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK Mutation

United States, Canada
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Breast Cancer | Stage IV Breast Cancer

United States, Canada, Israel, Saudi Arabia, South Africa
AstraZeneca
Daiichi Sankyo

Not yet recruiting

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada (HER-TEMPO)

Metastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Canada
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditions

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine... and other conditions

United States, Korea, Republic of, Canada
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer

Taiwan, Korea, Republic of, Greece, Spain, United States, Israel, France, Japan, Belgium, Poland, China, Singapore, Australia, Hungary, Czechia, Italy, South Africa, Hong Kong, Chile, Brazil, Argentina, Austria, Canada, Germany, Portugal, United Kingdom
Spanish Breast Cancer Research Group
Pierre Fabre Laboratories; Puma Biotechnology, Inc.

Recruiting

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib (DIANER)

HER2 Positive Breast Cancer | Hormone Receptor Positive | Early-stage Breast Cancer

Spain
Sunnybrook Health Sciences Centre
AFP Innovation Fund

Recruiting

Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients

Breast Cancer | Breast Neoplasms | Metastatic Breast Cancer | Cancer, Breast

Canada

Clinical Trials on Stage IB Breast Cancer in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations